Oncology MRI

Catch up on the most well-viewed video interviews from Diagnostic Imaging in September 2026.

A deep learning model developed for predicting BI-RADS assessments from dynamic contrast-enhanced (DCE) breast MRI had over a 14 percent lower AUC than radiologist evaluation in external validation testing.

In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.

For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.

In a recent interview, Stamatia Destounis, MD, FACR, shared her perspective on recent changes to the BI-RADS system, offering insights on contrast-enhanced mammography, reporting changes for breast MRI and ultrasound, and the importance of auditing for BI-RADS category 3 assessments.

Catch up on the top radiology content of the past week.

New research suggests that photon-counting CT provides comparable sensitivity to breast MRI for lesion characterization, higher accuracy than MRI for nodal metastasis and lower detection of microcalcifications in comparison to full-field digital mammography.

Catch up on the most-well viewed radiology content in August 2026.

This summer's breast imaging research spanned digital breast tomosynthesis (DBT) efficiency gains, AI models that flag cancer risk years before diagnosis, a cautionary study on automation bias, and advances in ultrasound, MRI, and contrast-enhanced mammography (CEM). Here is a look back at the most well-viewed breast imaging content of the summer.

Catch up on the top AI-related news and research in radiology over the past month.

Catch up on the top radiology content of the past week.

New research revealed that risk-stratified MRI surveillance in patients with cirrhosis led to over a 10 percent increase in early detection and over a 44 percent decrease in surveillance exams in comparison to reported results with semiannual ultrasound monitoring.

Catch up on the latest contrast-enhanced mammography research, CT insights, MRI studies and FDA approvals in PET imaging with our Weekly Scan.

In comparison to standard readout-segmented echo-planar imaging, the combination of deep learning reconstruction and multi-shot diffusion-weighted imaging (DWI) offered significantly higher SNR, CNR and lesion contrast with a greater than a two-minute reduction in scan time.

Noting the rising imaging volume and dearth of MRI scanner availability, the authors of a new literature review explore the utility and impact of workflow redesign, staff training, scheduling improvements and AI advances for enhancing MRI workflows.

In a recently published review of the BI-RADS v2025 manual, leading breast radiologists offered pertinent insights on key changes for reporting of mammogram, breast ultrasound and breast MRI interpretation and assessment.

Catch up on the top radiology content of the past week.

For biopsy-naïve patients who had radical prostatectomy for prostate cancer, new research suggests that biparametric MRI is comparable to multiparametric MRI for detecting extraprostatic extension.

Catch up on the top radiology content of the past week.

A model combining MRI and ultrasound findings yielded a 93 percent AUC for predicting microvascular invasion in hepatocellular carcinoma.

Catch up on the top radiology content of the past week.

Researchers said the combination of 18F-flotufolastat PET/MRI may lead to a 57 percent reduction of prostate biopsies in comparison to a 25 percent reduction with prostate MRI alone.

In comparison to everolimus, the peptide receptor radionuclide therapy (177Lu)Lu-edotreotide provided over a nine month longer median progression-free survival for patients with gastroenteropancreatic neuroendocrine tumours (GEP NETs), according to new phase 3 research.

Catch up on the top radiology content of the past week.

In comparison to the 2009 International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer, researchers found that the updated 2023 FIGO system had over a 17 percent decrease for substage agreement between pelvic MRI and pathology findings.